Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

310 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer.
Hanna N, Ohana P, Konikoff FM, Leichtmann G, Hubert A, Appelbaum L, Kopelman Y, Czerniak A, Hochberg A. Hanna N, et al. Among authors: hubert a. Cancer Gene Ther. 2012 Jun;19(6):374-81. doi: 10.1038/cgt.2012.10. Epub 2012 Apr 13. Cancer Gene Ther. 2012. PMID: 22498722 Clinical Trial.
Oncofetal H19 RNA promotes tumor metastasis.
Matouk IJ, Raveh E, Abu-lail R, Mezan S, Gilon M, Gershtain E, Birman T, Gallula J, Schneider T, Barkali M, Richler C, Fellig Y, Sorin V, Hubert A, Hochberg A, Czerniak A. Matouk IJ, et al. Among authors: hubert a. Biochim Biophys Acta. 2014 Jul;1843(7):1414-26. doi: 10.1016/j.bbamcr.2014.03.023. Epub 2014 Apr 2. Biochim Biophys Acta. 2014. PMID: 24703882 Free article.
A phase 1/2a, dose-escalation, safety, pharmacokinetic, and preliminary efficacy study of intraperitoneal administration of BC-819 (H19-DTA) in subjects with recurrent ovarian/peritoneal cancer.
Lavie O, Edelman D, Levy T, Fishman A, Hubert A, Segev Y, Raveh E, Gilon M, Hochberg A. Lavie O, et al. Among authors: hubert a. Arch Gynecol Obstet. 2017 Mar;295(3):751-761. doi: 10.1007/s00404-017-4293-0. Epub 2017 Feb 3. Arch Gynecol Obstet. 2017. PMID: 28154921 Free PMC article. Clinical Trial.
Mutant KRAS is a druggable target for pancreatic cancer.
Zorde Khvalevsky E, Gabai R, Rachmut IH, Horwitz E, Brunschwig Z, Orbach A, Shemi A, Golan T, Domb AJ, Yavin E, Giladi H, Rivkin L, Simerzin A, Eliakim R, Khalaileh A, Hubert A, Lahav M, Kopelman Y, Goldin E, Dancour A, Hants Y, Arbel-Alon S, Abramovitch R, Shemi A, Galun E. Zorde Khvalevsky E, et al. Among authors: hubert a. Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20723-8. doi: 10.1073/pnas.1314307110. Epub 2013 Dec 2. Proc Natl Acad Sci U S A. 2013. PMID: 24297898 Free PMC article.
RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients.
Golan T, Khvalevsky EZ, Hubert A, Gabai RM, Hen N, Segal A, Domb A, Harari G, David EB, Raskin S, Goldes Y, Goldin E, Eliakim R, Lahav M, Kopleman Y, Dancour A, Shemi A, Galun E. Golan T, et al. Among authors: hubert a. Oncotarget. 2015 Sep 15;6(27):24560-70. doi: 10.18632/oncotarget.4183. Oncotarget. 2015. PMID: 26009994 Free PMC article. Clinical Trial.
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
Domchek SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Loman N, Robertson JD, Mann H, Kaufman B. Domchek SM, et al. Among authors: hubert a. Gynecol Oncol. 2016 Feb;140(2):199-203. doi: 10.1016/j.ygyno.2015.12.020. Epub 2015 Dec 23. Gynecol Oncol. 2016. PMID: 26723501 Free PMC article. Clinical Trial.
310 results